Recent advancements in stem cell therapy have led to an increased interest within\nthe auditory community in exploring the potential of mesenchymal stem cells (MSCs) in the treatment\nof inner ear disorders. However, the biocompatibility of MSCs with the inner ear, especially when\ndelivered non-surgically and in the immunocompetent cochlea, is not completely understood. In this\nstudy, we determined the effect of intratympanic administration of rodent bone marrow MSCs\n(BM-MSCs) on the inner ear in an immunocompetent rat model. The administration of MSCs did not\nlead to the generation of any oxidative stress in the rat inner ear. There was no significant production\nof proinflammatory cytokines, tumor necrosis factor (TNF), interleukin (IL)-1, IL-6 and IL-12, due\nto BM-MSCs administration into the rat cochlea. BM-MSCs do not activate caspase 3 pathway, which\nplays a central role in sensory cell damage. Additionally, transferase dUTP nick end labeling (TUNEL)\nstaining determined that there was no significant cell death associated with the administration of\nBM-MSCs. The results of the present study suggest that trans-tympanic administration of BM-MSCs\ndoes not result in oxidative stress or inflammatory response in the immunocompetent rat cochlea.
Loading....